Patents Assigned to Impax Laboratories, Inc.
-
Publication number: 20200009062Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.Type: ApplicationFiled: September 17, 2019Publication date: January 9, 2020Applicant: Impax Laboratories, Inc.Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
-
Publication number: 20190254978Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.Type: ApplicationFiled: March 21, 2019Publication date: August 22, 2019Applicant: Impax Laboratories, Inc.Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
-
Patent number: 10292935Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.Type: GrantFiled: April 6, 2016Date of Patent: May 21, 2019Assignee: Impax Laboratories, Inc.Inventors: Ann Hsu, Liang C. Dong, Amy Ding, Suneel Gupta
-
Patent number: 9901640Abstract: A modified release levodopa dosage form.Type: GrantFiled: December 19, 2016Date of Patent: February 27, 2018Assignee: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim Kou, Laman Alani
-
Patent number: 9533046Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: GrantFiled: December 4, 2015Date of Patent: January 3, 2017Assignee: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim Kou, Laman Alani
-
Patent number: 9463246Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: GrantFiled: September 18, 2013Date of Patent: October 11, 2016Assignee: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim H. Kou, Laman Lynn Alani
-
Patent number: 9089608Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: GrantFiled: September 18, 2013Date of Patent: July 28, 2015Assignee: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim H. Kou, Laman Lynn Alani
-
Patent number: 9089607Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: GrantFiled: May 22, 2013Date of Patent: July 28, 2015Assignee: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim H. Kou, Laman Lynn Alani
-
Patent number: 8557283Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: GrantFiled: December 11, 2012Date of Patent: October 15, 2013Assignee: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim H. Kou, Laman Lynn Alani
-
Patent number: 8454998Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: GrantFiled: February 6, 2012Date of Patent: June 4, 2013Assignee: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim H. Kou, Laman Alani
-
Patent number: 8377474Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: GrantFiled: December 26, 2008Date of Patent: February 19, 2013Assignee: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim H. Kou, Laman Alani
-
Publication number: 20120177731Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: ApplicationFiled: February 6, 2012Publication date: July 12, 2012Applicant: Impax Laboratories, Inc.Inventors: Ann Hsu, Jim H. Kou, Laman Alani
-
Patent number: 8007827Abstract: The present invention relates generally to pharmaceutical dosage forms comprising: an absorption window active agent; a controlled release component comprising enteric-coated controlled release beads, wherein the enteric-coated release beads comprise at least two pH-sensitive polymer layers. The controlled-release dosage forms provide good bioavailability of absorption window active agents.Type: GrantFiled: September 30, 2005Date of Patent: August 30, 2011Assignee: Impax Laboratories, Inc.Inventors: Chien-Hsuan Han, Larry Hsu, Ann F. Hsu
-
Patent number: 7094427Abstract: The present invention relates to dosage forms of a combination of carbidopa and levodopa comprising both immediate release and controlled release components for the treatment of ailments associated with depleted amounts of dopamine in a patient's brain tissue.Type: GrantFiled: September 12, 2002Date of Patent: August 22, 2006Assignee: Impax Laboratories, Inc.Inventors: Chien-Hsuan Han, Larry Hsu, Ann F. Hsu
-
Publication number: 20050147670Abstract: The invention is directed to pharmaceutical dosage forms having immediate release via rapid oral disintegration, specifically, orally disintegrating tablets containing levodopa and carbidopa. The invention further provides formulations containing relatively increased amounts of carbidopa than previously available, including, for example, formulations containing carbidopa-levodopa ratios of about 1:1 to about 1:3.Type: ApplicationFiled: December 30, 2004Publication date: July 7, 2005Applicant: IMPAX Laboratories Inc.Inventors: Ann Hsu, Chien-Hsuan Han
-
Patent number: 6531158Abstract: The present invention provides a drug delivery system for the oral administration of a hydrophobic active ingredient. The active ingredient's post-ingestion dissolution rate and its corresponding bioavailability can be optimized by intimately mixing a micronized hydrophobic drug with suitably sized inert particles to a dispersion that will facilitate desired bioavailability. In a particular embodiment, the hydrophobic active ingredient is fenofibrate. Suitably sized inert particles include microcrystalline cellulose and lactose. Dispersion may be monitored by microscopic visualization.Type: GrantFiled: August 9, 2000Date of Patent: March 11, 2003Assignee: Impax Laboratories, Inc.Inventors: Ching-Ling Teng, Charles Hsiao, Joshua Gatts
-
Patent number: 6333332Abstract: This invention is directed to stabilized pharmaceutical preparations containing bupropion hydrochloride. The preferred stabilizers comprise salts of organic bases including those selected from the group consisting of creatinine hydrochloride, pyridoxine hydrochloride, and thiamine hydrochloride. Another stabilizer utilized includes a salt of an inorganic acid such as potassium phosphate monobasic. The compositions retain at least 80% of the initial potency of bupropion hydrochloride after one week at 60° and 75% relative humidity (RH), as well as four or twelve weeks at 40° C. and 75% RH.Type: GrantFiled: August 25, 2000Date of Patent: December 25, 2001Assignee: Impax Laboratories, Inc.Inventors: Chien-Hsuan Han, Gary Liaw